NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Forecast, Price & News $5.91 -0.09 (-1.50%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$5.84▼$6.1750-Day Range$5.65▼$9.9352-Week Range$2.00▼$10.30Volume100,696 shsAverage Volume153,207 shsMarket Capitalization$106.62 millionP/E RatioN/ADividend YieldN/APrice Target$18.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Achieve Life Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside215.8% Upside$18.67 Price TargetShort InterestBearish3.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 4 Articles This WeekInsider TradingAcquiring Shares$27,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.59) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector473rd out of 981 stocksDiagnostic Substances Industry7th out of 15 stocks 3.5 Analyst's Opinion Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.67, Achieve Life Sciences has a forecasted upside of 215.8% from its current price of $5.91.Amount of Analyst CoverageAchieve Life Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.51% of the outstanding shares of Achieve Life Sciences have been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Achieve Life Sciences has recently increased by 11.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACHV. Previous Next 3.0 News and Social Media Coverage News SentimentAchieve Life Sciences has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.Search Interest22 people have searched for ACHV on MarketBeat in the last 30 days. This is an increase of 69% compared to the previous 30 days.MarketBeat Follows7 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 21.11% of the stock of Achieve Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.59) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchieve Life Sciences has a P/B Ratio of 12.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Achieve Life Sciences (NASDAQ:ACHV) StockAchieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.Read More Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHV Stock News HeadlinesJune 6, 2023 | finance.yahoo.comAchieve Life Sciences Announces Participation at Upcoming Investor ConferencesJune 3, 2023 | americanbankingnews.comJohn Bencich Buys 5,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) StockJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 3, 2023 | americanbankingnews.comLake Street Capital Cuts Achieve Life Sciences (NASDAQ:ACHV) Price Target to $19.00June 1, 2023 | msn.comLake Street Maintains Achieve Life Sciences (ACHV) Buy RecommendationMay 31, 2023 | bizjournals.comAchieve Life Sciences raises $16.5M in pursuit of anti-smoking drugMay 31, 2023 | americanbankingnews.comAchieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest UpdateMay 25, 2023 | msn.comAchieve Life Sciences stock down on pricing $16.5M stock offeringJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 25, 2023 | finance.yahoo.comACHV: ORCA-3 ToplineMay 25, 2023 | finance.yahoo.comAchieve Life Sciences Announces Pricing of $16.5 Million Registered Direct OfferingMay 24, 2023 | finance.yahoo.comAchieve Life Sciences, Inc.'s (NASDAQ:ACHV) Shift From Loss To ProfitMay 23, 2023 | markets.businessinsider.comLadenburg Thalmann & Co. Sticks to Their Buy Rating for Achieve Life Sciences (ACHV)May 23, 2023 | finance.yahoo.comCan't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation TrialMay 23, 2023 | finance.yahoo.comAchieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical TrialMay 17, 2023 | finance.yahoo.comAchieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley BankMay 16, 2023 | americanbankingnews.comAchieve Life Sciences, Inc. (NASDAQ:ACHV) Expected to Earn Q2 2023 Earnings of ($0.40) Per ShareMay 13, 2023 | americanbankingnews.comAchieve Life Sciences (NASDAQ:ACHV) and Virax Biolabs Group (NASDAQ:VRAX) Head to Head SurveyMay 13, 2023 | americanbankingnews.comMaxim Group Raises Achieve Life Sciences (NASDAQ:ACHV) Price Target to $20.00May 11, 2023 | seekingalpha.comAchieve Life Sciences GAAP EPS of -$0.50 beats by $0.19May 11, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Achieve Life Sciences (ACHV), NGM Biopharmaceuticals (NGM) and Cutera (CUTR)May 11, 2023 | americanbankingnews.comAchieve Life Sciences (NASDAQ:ACHV) PT Raised to $20.00 at Maxim GroupMay 10, 2023 | finance.yahoo.comACHV: First Quarter ResultsMay 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Achieve Life Sciences (ACHV) and uniQure (QURE)May 10, 2023 | finance.yahoo.comQ1 2023 Achieve Life Sciences Inc Earnings CallMay 9, 2023 | finance.yahoo.comAchieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate UpdateMay 8, 2023 | investing.comAchieve Life Sciences (ACHV) Earnings Dates & ReportsSee More Headlines ACHV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACHV Company Calendar Last Earnings3/16/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACHV CUSIP68230A10 CIK949858 Webachievelifesciences.com Phone(604) 210-2217Fax425-686-1600Employees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.67 High Stock Price Forecast$20.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+208.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-762.66% Return on Assets-161.40% Debt Debt-to-Equity Ratio0.12 Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book13.15Miscellaneous Outstanding Shares18,040,000Free Float17,680,000Market Cap$109.14 million OptionableNot Optionable Beta1.56 Key ExecutivesJohn A. BencichDirector, Chief Executive & Financial OfficerCindy A. JacobsPresident, Chief Medical Officer & DirectorAnthony John ClarkeChief Scientific OfficerJaime XinosExecutive Vice President-CommercialJerry WanPrincipal Accounting OfficerKey CompetitorsAlpha TeknovaNASDAQ:TKNOMyMD PharmaceuticalsNASDAQ:MYMDImmuCellNASDAQ:ICCCOncoCyteNASDAQ:OCXNymox PharmaceuticalNASDAQ:NYMXView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 3,375 shares on 6/1/2023Ownership: 0.084%John BencichBought 5,000 shares on 5/30/2023Total: $27,500.00 ($5.50/share)Geode Capital Management LLCBought 95,118 shares on 5/16/2023Ownership: 1.000%Susquehanna International Group LLPBought 39,100 shares on 5/16/2023Ownership: 0.000%State Street CorpBought 4,700 shares on 5/16/2023Ownership: 0.152%View All Insider TransactionsView All Institutional Transactions ACHV Stock - Frequently Asked Questions Should I buy or sell Achieve Life Sciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares. View ACHV analyst ratings or view top-rated stocks. What is Achieve Life Sciences' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year price targets for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 208.5% from the stock's current price. View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts. How have ACHV shares performed in 2023? Achieve Life Sciences' stock was trading at $2.45 on January 1st, 2023. Since then, ACHV shares have increased by 146.9% and is now trading at $6.05. View the best growth stocks for 2023 here. Are investors shorting Achieve Life Sciences? Achieve Life Sciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 633,200 shares, an increase of 11.2% from the April 30th total of 569,600 shares. Based on an average daily volume of 156,300 shares, the short-interest ratio is currently 4.1 days. View Achieve Life Sciences' Short Interest. When is Achieve Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ACHV earnings forecast. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.07. During the same period in the prior year, the business earned ($0.76) earnings per share. When did Achieve Life Sciences' stock split? Shares of Achieve Life Sciences reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI). What is Achieve Life Sciences' stock symbol? Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV." Who are Achieve Life Sciences' major shareholders? Achieve Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.00%), LPL Financial LLC (0.80%), Long Focus Capital Management LLC (0.78%), Perkins Capital Management Inc. (0.77%), Raymond James & Associates (0.58%) and Susquehanna International Group LLP (0.00%). View institutional ownership trends. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Achieve Life Sciences' stock price today? One share of ACHV stock can currently be purchased for approximately $6.05. How much money does Achieve Life Sciences make? Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $109.14 million. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis. How can I contact Achieve Life Sciences? Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600. This page (NASDAQ:ACHV) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.